Abstract
Oncogenic B-Raf has been identified in a variety of cancers with high incidence, especially in malignant melanoma and thyroid cancer. Most B-Raf mutations elicit elevated kinase activity and the constitutive activation of Ras/Raf/MEK/ERK pathway, which induces proliferation and promotes malignant transformation. Therefore, B-Raf inhibitors, targeting B-Raf or mutated B-Raf, have received increasing momentum in oncology drug discovery arena. This review focuses on the diverse small-molecule inhibitors of B-Raf kinase recently reported in the literature, including those currently in clinical and preclinical phase. They are described as two categories, type I or type II kinase inhibitors, based on their different mechanism of action with active or inactive conformations of the B-Raf kinase derived from the available crystal structures or molecular docking analysis. A particular emphasis is placed on their binding modes and the structure-activity relationship (SAR) of each chemical structure class.
Keywords: B-Raf, B-RafV600E, B-Raf kinase inhibitors, binding mode, SAR, mechanism of action
Current Medicinal Chemistry
Title: Recent Advances in the Research and Development of B-Raf Inhibitors
Volume: 17 Issue: 16
Author(s): Hui-Fang Li, Yadong Chen, Sha-Sha Rao, Xiu-Mei Chen, Hai-Chun Liu, Ji-Hong Qin, Wei-Fang Tang, Yue-Wang, Xiang Zhou and Tao Lu
Affiliation:
Keywords: B-Raf, B-RafV600E, B-Raf kinase inhibitors, binding mode, SAR, mechanism of action
Abstract: Oncogenic B-Raf has been identified in a variety of cancers with high incidence, especially in malignant melanoma and thyroid cancer. Most B-Raf mutations elicit elevated kinase activity and the constitutive activation of Ras/Raf/MEK/ERK pathway, which induces proliferation and promotes malignant transformation. Therefore, B-Raf inhibitors, targeting B-Raf or mutated B-Raf, have received increasing momentum in oncology drug discovery arena. This review focuses on the diverse small-molecule inhibitors of B-Raf kinase recently reported in the literature, including those currently in clinical and preclinical phase. They are described as two categories, type I or type II kinase inhibitors, based on their different mechanism of action with active or inactive conformations of the B-Raf kinase derived from the available crystal structures or molecular docking analysis. A particular emphasis is placed on their binding modes and the structure-activity relationship (SAR) of each chemical structure class.
Export Options
About this article
Cite this article as:
Li Hui-Fang, Chen Yadong, Rao Sha-Sha, Chen Xiu-Mei, Liu Hai-Chun, Qin Ji-Hong, Tang Wei-Fang, Yue-Wang , Zhou Xiang and Lu Tao, Recent Advances in the Research and Development of B-Raf Inhibitors, Current Medicinal Chemistry 2010; 17 (16) . https://dx.doi.org/10.2174/092986710791111242
DOI https://dx.doi.org/10.2174/092986710791111242 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Image-Based Stem-Cell Labeling and Tracking, and Scaffold-Based Organ Development in Cardiovascular Disease
Recent Patents on Medical Imaging High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer’s Disease
Current Alzheimer Research Current Status of Computer-Aided Drug Design for Type 2 Diabetes
Current Computer-Aided Drug Design Nanoparticles: Properties and Applications in Cancer Immunotherapy
Current Pharmaceutical Design Mechanisms of CTLA-4-Ig in Tolerance Induction
Current Pharmaceutical Design The Vitamin D Neuroendocrine System as a Target for Novel Neurotropic Drugs
CNS & Neurological Disorders - Drug Targets Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The INSL3-LGR8 Hormonal System in Humans: Testicular Descent, Cryptorchidism and Testicular Functions
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Mitochondrial Uncoupler Proteins
Current Enzyme Inhibition Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Promoters and Control Elements: Designing Expression Cassettes for Gene Therapy
Current Gene Therapy Emerging Strategies and Agents to Lower Cardiovascular Risk by Increasing High Density Lipoprotein Cholesterol Levels
Current Medicinal Chemistry FDG-PET Imaging in Large Vessel Vasculitis and Polymyalgia Rheumatica: A Personal View
Current Immunology Reviews (Discontinued) <sup>18</sup>F-DOPA and <sup>18</sup>F-FDG PET/CT, Scintigraphic Localization and Radioguided Surgery of Recurrent Medullary Thyroid Cancer: Two Case Reports
Current Radiopharmaceuticals Comparison of Radiohaloanalogues of Meta-Iodobenzylguanidine (MIBG) for a Combined Gene- and Targeted Radiotherapy Approach to Bladder Carcinoma
Medicinal Chemistry Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine Mechanism of Action of Flavonoids as Anti-inflammatory Agents: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Diabetic Patients with Psychiatric Illness
Current Diabetes Reviews Bone Metastases Radiopharmaceuticals: An Overview
Current Radiopharmaceuticals Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery